Kymera Therapeutics, Inc. (KYMR)
118.63
-0.42
(-0.35%)
USD |
NASDAQ |
Sep 02, 16:00
119.00
+0.37
(+0.31%)
After-Hours: 20:00
Kymera Therapeutics Research and Development Expense (Annual) : 308.26M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 308.26M |
| December 31, 2024 | 232.88M |
| December 31, 2023 | 185.52M |
| December 31, 2022 | 161.27M |
| Date | Value |
|---|---|
| December 31, 2021 | 134.62M |
| December 31, 2020 | 60.34M |
| December 31, 2019 | 37.16M |
| December 31, 2018 | 17.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |
| Sarepta Therapeutics, Inc. | 1.493B |
| Anixa Biosciences, Inc. | 5.071M |